Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening (Q39592286)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 14, 2011

Language	Label	Description	Also known as
English	Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening	scientific article published on February 14, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening (English)

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

author name string

Kamil Paruch

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Marc Labroli

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Frances Shanahan

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Nicole Davis

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Lorena Taricani

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Derek Wiswell

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Wolfgang Seghezzi

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ervin Penaflor

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Bhagyashree Bhagwat

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Wei Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Danling Gu

13

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yunsheng Hsieh

14

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Suining Lee

15

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ming Liu

16

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

David Parry

17

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Timothy J. Guzi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21321066

24 November 2024

Michael P. Dwyer

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21321066

24 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21321066

24 November 2024

publication date

14 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://aacrjournals.org/mct/article-pdf/10/4/591/2319620/591.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21321066

24 November 2024

http://intl-mct.aacrjournals.org/cgi/content/abstract/10/4/591

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21321066

24 November 2024

https://aacrjournals.org/mct/article-pdf/10/4/591/2319620/591.pdf

Portable Document Format

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

591-602

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

treatment of cancer

1

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Turning the replication checkpoint on and off.

3

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects

4

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Chk1 is essential for tumor cell viability following activation of the replication checkpoint

5

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage

6

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Replication stress activates DNA polymerase alpha-associated Chk1.

7

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Cdc25 Mitotic Inducer Targeted by Chk1 DNA Damage Checkpoint Kinase

8

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation.

9

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Conservation of the Chk1 Checkpoint Pathway in Mammals: Linkage of DNA Damage to Cdk Regulation Through Cdc25

10

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation

12

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.

13

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.

14

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

15

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2

16

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Unmasking the redundancy between Cdk1 and Cdk2 at G2 phase in human cancer cell lines

18

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

19

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

20

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

The role of hyphenated chromatography-mass spectrometry techniques in exploratory drug metabolism and pharmacokinetics

21

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine

22

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Structure-guided discovery of cyclin-dependent kinase inhibitors

23

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Spreading the signal: dissociation of Chk1 from chromatin.

24

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system

25

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells

26

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer

28

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

29

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

30

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing

31

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

32

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Chk1 and Chk2 kinases in checkpoint control and cancer

33

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

34

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation

35

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

36

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1

37

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

A requirement for replication in activation of the ATR-dependent DNA damage checkpoint

38

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation

39

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

The ATR pathway: fine-tuning the fork

40

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial

44

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.

45

1 reference

10.1158/1535-7163.MCT-10-0928

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0928

24 November 2024

Identifiers

10.1158/1535-7163.MCT-10-0928

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

release_5m65cicw2bejbci27ndyqkcnpy

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39592286&oldid=2279618117"